WO2006083455A1 - Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions - Google Patents
Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions Download PDFInfo
- Publication number
- WO2006083455A1 WO2006083455A1 PCT/US2005/047483 US2005047483W WO2006083455A1 WO 2006083455 A1 WO2006083455 A1 WO 2006083455A1 US 2005047483 W US2005047483 W US 2005047483W WO 2006083455 A1 WO2006083455 A1 WO 2006083455A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nerve endings
- trigeminal
- botulinum toxin
- occipital
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002596366A CA2596366A1 (en) | 2005-02-01 | 2005-12-29 | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
EP05855968.3A EP1846018B1 (en) | 2005-02-01 | 2005-12-29 | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
BRPI0519908-5A BRPI0519908A2 (en) | 2005-02-01 | 2005-12-29 | targeted distribution of botulinum toxin for the treatment and prevention of trigeminal autonomic headache, migraine and vascular conditions |
AU2005326660A AU2005326660B2 (en) | 2005-02-01 | 2005-12-29 | Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
JP2007554095A JP2008528685A (en) | 2005-02-01 | 2005-12-29 | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal and autonomic headache, migraine and vascular symptoms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59364105P | 2005-02-01 | 2005-02-01 | |
US60/593,641 | 2005-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006083455A1 true WO2006083455A1 (en) | 2006-08-10 |
Family
ID=36777553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/047483 WO2006083455A1 (en) | 2005-02-01 | 2005-12-29 | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
Country Status (7)
Country | Link |
---|---|
US (3) | US7655244B2 (en) |
EP (1) | EP1846018B1 (en) |
JP (2) | JP2008528685A (en) |
AU (1) | AU2005326660B2 (en) |
BR (1) | BRPI0519908A2 (en) |
CA (1) | CA2596366A1 (en) |
WO (1) | WO2006083455A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009124046A1 (en) * | 2008-04-03 | 2009-10-08 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
AU2013202887A1 (en) * | 2008-04-03 | 2013-05-09 | Allergan, Inc | Suture line administration technique using botulinum toxins |
AU2013311572B2 (en) * | 2012-09-06 | 2017-01-12 | Norwegian University Of Science And Technology (Ntnu) | Treatment of headache by injection of neuroinhibitory substance to sphenopalatine ganglion or otic ganglion |
US10201497B2 (en) | 2012-03-12 | 2019-02-12 | Miotox, Llc | Treatment of migraine headaches with presynaptic neurotoxin |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153876A1 (en) | 2003-02-24 | 2006-07-13 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease |
US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7922983B2 (en) * | 2005-07-28 | 2011-04-12 | Kimberly-Clark Worldwide, Inc. | Sterilization wrap with additional strength sheet |
US20080021437A1 (en) * | 2006-04-27 | 2008-01-24 | Boyd James P | Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
JP2013510193A (en) * | 2009-11-09 | 2013-03-21 | サンダース,イラ | Treatment of sleep-disordered breathing using neurotoxins |
US20120251574A1 (en) * | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
WO2012174123A1 (en) | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
US20130236446A1 (en) | 2012-03-12 | 2013-09-12 | William J. Binder | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth |
US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
MX370929B (en) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Compositions and methods for safe treatment of rhinitis. |
US9516995B2 (en) | 2013-12-17 | 2016-12-13 | Biovision Technologies, Llc | Surgical device for performing a sphenopalatine ganglion block procedure |
US9694163B2 (en) | 2013-12-17 | 2017-07-04 | Biovision Technologies, Llc | Surgical device for performing a sphenopalatine ganglion block procedure |
US10016580B2 (en) | 2013-12-17 | 2018-07-10 | Biovision Technologies, Llc | Methods for treating sinus diseases |
US9510743B2 (en) | 2013-12-17 | 2016-12-06 | Biovision Technologies, Llc | Stabilized surgical device for performing a sphenopalatine ganglion block procedure |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
EP3146894A1 (en) * | 2015-09-28 | 2017-03-29 | Essilor International (Compagnie Generale D'optique) | A user migraine analysis component |
WO2017100624A1 (en) * | 2015-12-11 | 2017-06-15 | Revance Therapeutics, Inc. | Botulinum toxin for primary disorders of mood and affect using neurotransmitter |
IT201800001119A1 (en) * | 2018-01-16 | 2019-07-16 | Francesco Giuseppe Bono | Regionalized and focused method of administering botulinum toxin by intradermal-subdermal-subcutaneous injection for the treatment of chronic intractable migraine and headache |
US10525240B1 (en) | 2018-06-28 | 2020-01-07 | Sandler Scientific LLC | Sino-nasal rinse delivery device with agitation, flow-control and integrated medication management system |
US20210177946A1 (en) * | 2018-08-28 | 2021-06-17 | Ira Sanders | Therapeutic medications for the sphenopalatine ganglion |
US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
KR102520625B1 (en) | 2019-10-18 | 2023-04-12 | 펜랜드 파운데이션 | botulinum toxin for use in therapy |
US11090371B1 (en) | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
WO2023287728A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714468A (en) | 1994-05-09 | 1998-02-03 | Binder; William J. | Method for reduction of migraine headache pain |
WO2005082339A2 (en) | 2004-02-26 | 2005-09-09 | Allergan, Inc. | Medicaments and methods for treating headache |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
BR9914891A (en) | 1998-10-27 | 2001-07-17 | Mayo Foundation | Wound healing improvement processes |
US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
KR100602308B1 (en) | 2001-07-27 | 2006-07-18 | 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 | Botulinum toxin in the treatment or prevention of acne |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
DE10150415A1 (en) | 2001-10-11 | 2003-05-15 | Andres O Ceballos-Baumann | Prophylaxis and treatment of depression and related affective disorders, comprises the administration of botulinum toxin, preferably by local intramuscular injection in the face, head and neck region |
US20030224019A1 (en) | 2002-03-01 | 2003-12-04 | O'brien Christopher | Methods of treating nerve entrapment syndromes |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
WO2004041317A1 (en) * | 2002-11-05 | 2004-05-21 | Jingjiao Guan | Self-folding polymer microparticles |
MXPA05009425A (en) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin. |
US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8048423B2 (en) | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US7270287B2 (en) | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
US9078892B2 (en) | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US9061025B2 (en) | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
-
2005
- 2005-12-07 US US11/296,079 patent/US7655244B2/en active Active
- 2005-12-29 BR BRPI0519908-5A patent/BRPI0519908A2/en not_active Application Discontinuation
- 2005-12-29 JP JP2007554095A patent/JP2008528685A/en active Pending
- 2005-12-29 WO PCT/US2005/047483 patent/WO2006083455A1/en active Application Filing
- 2005-12-29 EP EP05855968.3A patent/EP1846018B1/en not_active Not-in-force
- 2005-12-29 AU AU2005326660A patent/AU2005326660B2/en not_active Ceased
- 2005-12-29 CA CA002596366A patent/CA2596366A1/en not_active Abandoned
-
2009
- 2009-12-18 US US12/642,545 patent/US8241641B2/en active Active
-
2012
- 2012-03-28 JP JP2012073935A patent/JP2012131826A/en active Pending
- 2012-05-17 US US13/474,490 patent/US8603983B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714468A (en) | 1994-05-09 | 1998-02-03 | Binder; William J. | Method for reduction of migraine headache pain |
WO2005082339A2 (en) | 2004-02-26 | 2005-09-09 | Allergan, Inc. | Medicaments and methods for treating headache |
Non-Patent Citations (3)
Title |
---|
A. M. BLUMENFELD ET AL., HEADACHE, vol. 43, no. 8, September 2003 (2003-09-01), pages 884 - 891 |
G. E. BORODIC ET AL., THE JOURNAL OF PAIN, vol. 3, no. I, 2002, pages 21 - 27 |
W. EVANS ET AL., HEADACHE, vol. 43, no. 9, June 2003 (2003-06-01), pages 682 - 685 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530425B2 (en) | 2005-02-01 | 2013-09-10 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7981433B2 (en) | 2005-02-01 | 2011-07-19 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US8846622B2 (en) | 2005-02-01 | 2014-09-30 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US8241641B2 (en) | 2005-02-01 | 2012-08-14 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US8603983B2 (en) | 2005-02-01 | 2013-12-10 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
EP2392344A1 (en) * | 2008-04-03 | 2011-12-07 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
AU2013202887A1 (en) * | 2008-04-03 | 2013-05-09 | Allergan, Inc | Suture line administration technique using botulinum toxins |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
WO2009124046A1 (en) * | 2008-04-03 | 2009-10-08 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
AU2009231786B2 (en) * | 2008-04-03 | 2015-06-18 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
US9248168B2 (en) | 2008-04-03 | 2016-02-02 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
US9827297B2 (en) | 2008-04-03 | 2017-11-28 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
US10220079B2 (en) | 2008-04-03 | 2019-03-05 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
US10874722B2 (en) | 2008-04-03 | 2020-12-29 | Allergan, Inc. | Suture line administration technique using botulinum toxins |
US10201497B2 (en) | 2012-03-12 | 2019-02-12 | Miotox, Llc | Treatment of migraine headaches with presynaptic neurotoxin |
AU2013311572B2 (en) * | 2012-09-06 | 2017-01-12 | Norwegian University Of Science And Technology (Ntnu) | Treatment of headache by injection of neuroinhibitory substance to sphenopalatine ganglion or otic ganglion |
Also Published As
Publication number | Publication date |
---|---|
US20120040911A1 (en) | 2012-02-16 |
CA2596366A1 (en) | 2006-08-10 |
BRPI0519908A2 (en) | 2009-04-28 |
JP2012131826A (en) | 2012-07-12 |
AU2005326660A1 (en) | 2006-08-10 |
EP1846018B1 (en) | 2014-07-09 |
US7655244B2 (en) | 2010-02-02 |
US20060171963A1 (en) | 2006-08-03 |
US8603983B2 (en) | 2013-12-10 |
EP1846018A1 (en) | 2007-10-24 |
US8241641B2 (en) | 2012-08-14 |
AU2005326660B2 (en) | 2012-07-19 |
JP2008528685A (en) | 2008-07-31 |
US20120245096A1 (en) | 2012-09-27 |
EP1846018A4 (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8603983B2 (en) | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions | |
US8846622B2 (en) | Targeted delivery of botulinum toxin to the sphenopalatine ganglion | |
US5714468A (en) | Method for reduction of migraine headache pain | |
US8691769B2 (en) | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections | |
TWI323663B (en) | Use of botulinum toxin for the manufacture of medicament for treating sinus headache | |
JP2007528352A5 (en) | Treatment of chronic facial pain and headache associated with sinusitis with botulinum toxin | |
AU2011315962B2 (en) | Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders | |
WO2020047158A1 (en) | Therapeutic medications for the sphenopalatine ganglion | |
AU2012241076B2 (en) | Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions | |
US20210130445A1 (en) | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders | |
KR20230071072A (en) | Botulinum toxin composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005855968 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2596366 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005326660 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007554095 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005326660 Country of ref document: AU Date of ref document: 20051229 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0519908 Country of ref document: BR Kind code of ref document: A2 |